|
Indian pharma market growth slips to 4.5% in January
|
|
Yash Ved, Mumbai
February 09 , 2021
|
|
|
The Indian Pharmaceutical Market (IPM) has registered a growth of 4.5 per cent for the month of January 2021, as against growth of 8.5 per cent in December 2020.
According to AIOCD AWACS report, the IPM has recorded sales of Rs. 1,45,931 crore for moving annual total (MAT) basis during January 2021.
Amongst the top 10 corporates, Cipla exhibited the highest growth of 8.7 per cent, followed by Torrent Pharma at 6.6 per cent. Amongst the 11 to 25 ranked corporates, Glenmark Pharma exhibited highest growth of 15.7 per cent followed by Himalaya at 14.3 per cent.
Amongst the 26 to 50 ranked corporates, Apex Lab registered the highest growth of 21.6 per cent followed by Boehringer Ingelheim at 12.1 per cent. Amongst the 51 to 75 ranked corporates, Danone registered the highest growth of 34.1 per cent. Amongst the 76 to 100 ranked corporates, Unimed TL exhibited the highest growth at 18.2 per cent, followed by Unison at 9.3 per cent.
Cardiac registered a monthly growth of 8.8% in January 2021 as compared to 14.9% in December 2020, while anti-diabetic registered growth of 5.3% in January 2021 as compared to 9.9% in December 2020.
Respiratory segment posted negative growth and slumped to -14.1% in January 2021 as compared to -9.8 % in December 2020.
Few therapy areas that had slumped in Covid quarters are coming back to normal performance gradually.
Post unlockdown, since June 2020 the struggle for anti-infectives 5.2% in December 2020 continues -2.7% in January 2021 and its associated therapy like gastro exhibits growth of 14.3% as against 16.2% in December 2020.
Vitamins have bounced back has growth of 12.2% in January 2021. Pain and analgesics are at 5% in January 2021 as against -6% in December 2020.
|
|
|
|
|
|
|
|
TOPICS
|
The Food and Drug Administration (FDA), Maharashtra, has issued a public advisory urging citizens to report any misleadi ...
|
|
|
|
|